Twist Bioscience Corporation | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 92.8M
Gross Profit 46.0M 49.60%
Operating Income -41.6M -44.79%
Net Income -39.3M -42.38%
EPS (Diluted) $-0.66

Balance Sheet Metrics

Total Assets 595.6M
Total Liabilities 155.5M
Shareholders Equity 440.1M
Debt to Equity 0.35

Cash Flow Metrics

Operating Cash Flow -17.4M
Free Cash Flow -17.1M

Revenue & Profitability Trend

Twist Bioscience Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i313.0M245.1M203.6M132.3M90.1M
Cost of Goods Sold i179.6M155.4M119.3M80.6M61.4M
Gross Profit i133.3M89.7M84.2M51.7M28.7M
Gross Margin % i42.6%36.6%41.4%39.1%31.8%
Operating Expenses
Research & Development i90.9M106.9M120.3M69.1M43.0M
Selling, General & Administrative i218.4M189.7M212.9M135.9M103.3M
Other Operating Expenses i-----
Total Operating Expenses i309.2M296.6M333.3M205.0M146.3M
Operating Income i-175.9M-206.9M-249.0M-153.3M-117.6M
Operating Margin % i-56.2%-84.4%-122.3%-115.8%-130.5%
Non-Operating Items
Interest Income i15.3M14.4M3.1M435.0K1.5M
Interest Expense i29.0K5.0K80.0K367.0K787.0K
Other Non-Operating Income-47.6M-10.9M17.8M-836.0K-22.7M
Pre-tax Income i-208.2M-203.5M-228.3M-154.0M-139.5M
Income Tax i560.0K1.2M-10.4M-1.9M382.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-208.7M-204.6M-217.9M-152.1M-139.9M
Net Margin % i-66.7%-83.5%-107.0%-114.9%-155.3%
Key Metrics
EBITDA i-131.8M-163.9M-230.5M-144.4M-109.6M
EPS (Basic) i$-3.60$-3.60$-4.04$-3.15$-3.57
EPS (Diluted) i$-3.60$-3.60$-4.04$-3.15$-3.57
Basic Shares Outstanding i5801600056885000538850004825100039190000
Diluted Shares Outstanding i5801600056885000538850004825100039190000

Income Statement Trend

Twist Bioscience Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i226.3M286.5M378.7M465.8M93.7M
Short-term Investments i50.1M49.9M126.3M12.0M196.3M
Accounts Receivable i34.9M44.1M40.3M26.5M25.8M
Inventory i24.1M32.1M39.3M31.8M12.3M
Other Current Assets11.4M11.7M11.9M8.3M6.2M
Total Current Assets i346.8M424.3M596.5M546.5M334.9M
Non-Current Assets
Property, Plant & Equipment i158.4M176.0M137.2M110.0M71.0M
Goodwill i186.1M226.1M231.4M63.1M2.6M
Intangible Assets i14.5M54.5M59.7M18.3M307.0K
Long-term Investments-----
Other Non-Current Assets5.9M8.5M5.0M6.2M3.4M
Total Non-Current Assets i267.5M352.1M364.9M155.6M64.0M
Total Assets i614.3M776.4M961.4M702.1M398.9M
Liabilities
Current Liabilities
Accounts Payable i1.6M14.1M20.1M14.9M4.8M
Short-term Debt i14.8M14.9M13.6M9.8M9.7M
Current Portion of Long-term Debt-----
Other Current Liabilities961.0K430.0K12.6M6.1M1.9M
Total Current Liabilities i71.0M73.3M90.7M63.1M36.0M
Non-Current Liabilities
Long-term Debt i70.2M79.2M81.3M53.2M26.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities407.0K475.0K60.0K5.1M351.0K
Total Non-Current Liabilities i70.6M79.6M81.3M58.2M26.6M
Total Liabilities i141.6M153.0M172.0M121.3M62.6M
Equity
Common Stock i00000
Retained Earnings i-1.2B-1.0B-828.4M-610.6M-458.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i472.7M623.4M789.4M580.8M336.3M
Key Metrics
Total Debt i85.0M94.1M94.9M62.9M36.0M
Working Capital i275.8M350.9M505.8M483.4M298.8M

Balance Sheet Composition

Twist Bioscience Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-208.7M-204.6M-217.9M-152.1M-139.9M
Depreciation & Amortization i31.4M29.3M16.5M9.8M6.7M
Stock-Based Compensation i50.9M30.3M79.7M37.0M17.1M
Working Capital Changes i2.7M1.7M-5.1M-10.4M-18.8M
Operating Cash Flow i-121.7M-146.6M-119.5M-113.3M-135.7M
Investing Activities
Capital Expenditures i-5.1M-27.8M-101.9M-27.1M-9.9M
Acquisitions i00-13.9M-483.0K0
Investment Purchases i-51.9M-76.3M-217.6M-58.8M-202.9M
Investment Sales i53.9M154.7M100.5M242.5M98.1M
Investing Cash Flow i-3.1M50.6M-238.7M156.2M-114.6M
Financing Activities
Share Repurchases i-4.0M-4.4M-7.8M-10.8M-2.4M
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i00-1.6M-3.3M-3.3M
Financing Cash Flow i-4.0M-4.4M260.5M309.7M289.8M
Free Cash Flow i-69.2M-170.3M-226.2M-139.3M-152.1M
Net Change in Cash i-128.7M-100.4M-97.7M352.5M39.4M

Cash Flow Trend

Twist Bioscience Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.35
Forward P/E -11.53
Price to Book 3.53
Price to Sales 4.67
PEG Ratio 0.06

Profitability Ratios

Profit Margin -23.52%
Operating Margin -31.36%
Return on Equity -17.58%
Return on Assets -13.88%

Financial Health

Current Ratio 3.90
Debt to Equity 19.48
Beta 2.37

Per Share Data

EPS (TTM) $-1.44
Book Value per Share $7.95
Revenue per Share $6.10

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
twst1.7B-7.353.53-17.58%-23.52%19.48
Thermo Fisher 184.1B28.173.6413.42%15.24%69.62
Danaher 146.0B43.292.796.68%14.21%35.45
Neogen 1.2B865.000.59-41.88%-122.06%44.14
Grail 1.1B-0.490.49-17.68%-62.12%2.69
Opko Health 1.1B-17.130.82-13.16%-26.68%30.51

Financial data is updated regularly. All figures are in the company's reporting currency.